Global CRO market to grow to $57 billion by 2024, report forecasts
Growth in the CRO sector is expected to accompany growth of clinical trials, their complexity and regulatory requirements.
WuXi launches $250M fund to invest in life sciences startups
WuXi PharmaTech, a Chinese R&D powerhouse, is launching its second fund. It wants to invest $250 million into healthcare and life sciences startups in the U.S. and China.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Charles River, Wuxi PharmTech still on a roller coaster
It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX). Aiming to counter stiff opposition from some of its top institutional investors, Charles River Labs issued a revised presentation this week highlighting the benefits of the deal […]
Charles River Labs seeks support for merger with WuXi
Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients. Looking to bolster support for its proposed, $1.6 billion merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), Charles River Laboratories International Inc. (NYSE:CRL) is mounting […]
WuXi PharmaTech merger under review in Caymans
The Grand Court of the Cayman Islands plans to review a controversial, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL). Under the law of the Cayman Islands, where WuXi is incorporated, Grand Court approval is required to consummate the deal. WuXi said the court, equivalent to the […]
More balk at WuXi PharmaTech-Charles River deal
Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky. Neuberger Berman LLC, in a June 16 letter to CRL’s board of directors, said the merger is not in the best interest of CRL’s shareholders and […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Charles River Laboratories rebuffs investors protesting WuXi PharmaTech deal
Charles River Laboratories International Inc. (NYSE:CRL) responded to its largest shareholder’s protest about a proposed merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal was too good to pass up. In a letter to Jana Partners Inc. managing partner Barry Rosenstein, CRL CEO James Foster wrote that the hedge fund’s view of the […]
Lifecore Biomedical bought by California food-packaging firm
Another one bites the dust. If Minnesota is to build a vibrant biotechnology industry, as I wrote earlier today, it will need all of the homegrown talent and technology it can muster. Unfortunately, what little we did have went out the door today when Landec Corp., based in Menlo Park, Calif., said it will pay […]